a Represents net earnings attributable to AbbVie Inc. Acquisition and integration costs primarily reflect integration costs related to the Allergan acquisition, including a one-time gain of $169 ...

Other Stories is a recent discovery of mine as noted in my girly girl clothing haul. Where they really excel is in the classic styling, neutral colors and beautiful details. They have a few different ...

Below we've highlighted some notable scores on designer shoes, bags, and clothing from our favorite online luxury retailers — because everyone loves a good deal, whatever their budget may be.

However, the strong sales performance of drugs like Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant contributions from newer drugs Ubrelvy, Elahere, Epkinly and Qulipta ...

Elahere addresses the gap in effective medications for those platinum-resistant cancers which express high levels of folate receptor α (FRα). To determine your eligibility for Elahere, your doctor ...

A continuation of strong growth trends is my baseline assumption for the two products. Addition of Elahere is driving the return to growth of the oncology portfolio For the oncology segment ...

The primary objective of the present study was to assess the anti-tumor activity of a combination of trastuzumab with carboplatin and paclitaxel in patients with recurrent or refractory ovarian ...

More than 55% of patients taking Elahere, an ovarian cancer approved in 2022, may experience vision loss, according to a new study. The FDA's label for Elahere (mirvetuximab soravtansine ...

As the target FolRα has been validated by approval and successful launch of AbbVie's (ABBV) Elahere (acquired ImmunoGen for $10 billion last year), Sutro thinks its "best in class" candidate ...

Mirvetuximab soravtansine demonstrated efficacy in heavily pretreated patients with FRα+, platinum-sensitive ovarian cancer, achieving a 51.9% objective response rate in the PICCOLO trial.

Elahere (mirvetuximab soravtansine-gynx) is a brand-name injection that’s prescribed for certain types of cancer. As with other drugs, Elahere can cause side effects, such as eye problems, nerve ...

A newer addition to AbbVie's portfolio is Elahere, approved for the treatment of numerous cancers, including epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.